Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 2/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24025518 | 0.89 | NAMPT (0.39) | NAMPTMEN1KMT2AMERTKTGM2 | |
| SCHEMBL24025513 | 0.86 | F13A1 (0.41) | NAMPTMERTKTGM2F13A1TGM1 | |
| SCHEMBL24025550 | 0.85 | TGM2 (0.40) | NAMPTTGM2F13A1TGM1AOC2 | |
| SCHEMBL28589575 | 0.85 | TGM2 (0.40) | NAMPTTGM2F13A1TGM1AOC2 | |
| SCHEMBL24025663 | 0.85 | F13A1 (0.40) | NAMPTTGM2F13A1TGM1AOC2 | |
| Trifluoroacetic Acid SCHEMBL30597888 | 0.84 | MAOB (0.42) | AOC2MAOB | |
| Trifluoroacetic Acid SCHEMBL30526400 | 0.84 | MAOB (0.42) | AOC2MAOB | |
| SCHEMBL24025670 | 0.84 | NAMPT (0.42) | NAMPTMEN1KMT2AMERTKTGM2 | |
| SCHEMBL26345753 | 0.84 | MAOB (0.41) | MEN1KMT2AAOC2MAOBALDH1A1 | |
| SCHEMBL24057972 | 0.83 | NAMPT (0.46) | NAMPTMEN1KMT2ATGM2F13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213970-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-02-04 | — | — | US | disclosed |
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-112955215-B | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-112955214-B | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-3873600-B9 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-3873599-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3873600-B1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20210353608-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3873600-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2021-09-08 | — | — | EP | disclosed |
| CN-112955215-A | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112955214-A | Pyridylsulfonamide derivatives, pharmaceutical compositions and uses thereof | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353608-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | NAMPT 64/4885MEN1 965/4885KMT2A 2155/4885 |
| US-20210361637-A1 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ARSA, SULT1A1, SULT2A1 | NAMPT 64/4885MEN1 965/4885KMT2A 2155/4885 |
| US-12213970-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | ARSA, SULT1A1, SULT2A1 | NAMPT 64/4885MEN1 965/4885KMT2A 2155/4885 |
| US-12178809-B2 | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof | ARSA, SULT1A1, SULT2A1 | NAMPT 64/4885MEN1 965/4885KMT2A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.